IL234586A - Krabbe-Nucleoside Analogs 2-Converted to Antiviral Treatment - Google Patents

Krabbe-Nucleoside Analogs 2-Converted to Antiviral Treatment

Info

Publication number
IL234586A
IL234586A IL234586A IL23458614A IL234586A IL 234586 A IL234586 A IL 234586A IL 234586 A IL234586 A IL 234586A IL 23458614 A IL23458614 A IL 23458614A IL 234586 A IL234586 A IL 234586A
Authority
IL
Israel
Prior art keywords
nucleoside analogs
antiviral treatment
substituted carba
carba
substituted
Prior art date
Application number
IL234586A
Other languages
English (en)
Hebrew (he)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IL234586A publication Critical patent/IL234586A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/30—Vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL234586A 2012-03-13 2014-09-11 Krabbe-Nucleoside Analogs 2-Converted to Antiviral Treatment IL234586A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610411P 2012-03-13 2012-03-13
PCT/US2013/030196 WO2013138236A1 (en) 2012-03-13 2013-03-11 2'- substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
IL234586A true IL234586A (en) 2017-12-31

Family

ID=47997868

Family Applications (2)

Application Number Title Priority Date Filing Date
IL234586A IL234586A (en) 2012-03-13 2014-09-11 Krabbe-Nucleoside Analogs 2-Converted to Antiviral Treatment
IL256397A IL256397A (en) 2012-03-13 2017-12-18 Carba-nucleoside '2-converted analogs for antiviral therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL256397A IL256397A (en) 2012-03-13 2017-12-18 Carba-nucleoside '2-converted analogs for antiviral therapy

Country Status (18)

Country Link
US (4) US9481704B2 (show.php)
EP (4) EP3932931B1 (show.php)
JP (3) JP6242378B2 (show.php)
KR (1) KR102068856B1 (show.php)
CN (2) CN106749272B (show.php)
AU (2) AU2013232378B2 (show.php)
CA (1) CA2866381C (show.php)
EA (2) EA201791916A1 (show.php)
ES (4) ES2621217T3 (show.php)
IL (2) IL234586A (show.php)
IN (1) IN2014DN08505A (show.php)
MD (1) MD4496C1 (show.php)
MX (1) MX355267B (show.php)
NZ (1) NZ629996A (show.php)
PL (1) PL2834258T3 (show.php)
PT (1) PT2834258T (show.php)
SI (1) SI2834258T1 (show.php)
WO (1) WO2013138236A1 (show.php)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
IN2012DN00720A (show.php) 2009-07-06 2015-06-19 Ontorii Inc
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
US8633198B1 (en) 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
ES2621217T3 (es) 2012-03-13 2017-07-03 Gilead Sciences, Inc. Análogos de carba-nucleósido 2'-sustituidos para tratamiento antivírico
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
RS58437B1 (sr) * 2012-03-21 2019-04-30 Alios Biopharma Inc Supstituisani nukleozidi, nukleotidi i njihovi analozi
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
CA2939036C (en) * 2013-12-11 2020-09-22 Nant Holdings Ip, Llc Pyrazolopyrimidine derivatives useful in the treatment of influenza a and other rna viruses
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
AU2015213791B2 (en) * 2014-02-06 2019-11-14 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of Influenza RNA replication
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
EP3197457B1 (en) 2014-09-26 2022-11-09 Riboscience LLC 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
SI3236972T1 (sl) 2014-12-26 2021-12-31 Emory University Protivirusni derivati N4-hidroksicitidina
CA2998646C (en) 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP3615545B1 (en) 2017-04-24 2021-09-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
KR102813547B1 (ko) 2018-07-27 2025-05-27 코크리스탈 파마, 아이엔씨. 인플루엔자바이러스 복제 억제제로서의 피롤로[2,3-b]피리딘 유도체
CN113286793B (zh) 2018-09-10 2024-04-05 共结晶制药公司 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
EP4644394A2 (en) 2020-02-18 2025-11-05 Gilead Sciences, Inc. Antiviral compounds
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
JP2023518694A (ja) * 2020-03-22 2023-05-08 インスパーメッド コーポレーション 感染性疾患又は呼吸器疾患の予防的処置又は曝露後処置に使用するための抗ウイルス剤の組成物
JPWO2021200651A1 (show.php) * 2020-03-30 2021-10-07
CN111956630A (zh) * 2020-08-20 2020-11-20 大连理工大学 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20240049311A (ko) 2021-08-18 2024-04-16 길리애드 사이언시즈, 인코포레이티드 인지질 화합물 및 이의 제조 및 사용 방법
CA3229752A1 (en) * 2021-08-20 2023-02-23 Shionogi & Co., Ltd. Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (show.php) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5388571A (en) * 1987-07-17 1995-02-14 Roberts; Josephine A. Positive-pressure ventilator system with controlled access for nebulizer component servicing
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
CA2444415A1 (en) 1991-07-02 1993-01-21 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
CN101862345B (zh) * 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
DZ3487A1 (fr) * 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
WO2003062256A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
JP4398631B2 (ja) * 2002-07-12 2010-01-13 富山化学工業株式会社 新規なピラジン誘導体またはその塩並びにそれらを含有する抗ウイルス剤
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
EP2535345A1 (en) * 2007-01-12 2012-12-19 BioCryst Pharmaceuticals, Inc. Anticancer nucleoside analogs
US8242085B2 (en) 2007-05-10 2012-08-14 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
AU2009240642B2 (en) 2008-04-23 2013-08-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8455451B2 (en) * 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
DK2480559T3 (da) * 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
EP3150608B1 (en) * 2009-09-21 2019-04-10 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
ES2621217T3 (es) 2012-03-13 2017-07-03 Gilead Sciences, Inc. Análogos de carba-nucleósido 2'-sustituidos para tratamiento antivírico

Also Published As

Publication number Publication date
US20130243725A1 (en) 2013-09-19
EP3210993A1 (en) 2017-08-30
AU2013232378A1 (en) 2014-09-25
EP3932931B1 (en) 2024-11-20
HK1256856A1 (en) 2019-10-04
KR102068856B1 (ko) 2020-01-21
EA028928B9 (ru) 2018-05-31
CN104185638A (zh) 2014-12-03
EP3932931A1 (en) 2022-01-05
CN106749272A (zh) 2017-05-31
MX355267B (es) 2018-04-12
AU2013232378B2 (en) 2017-09-28
EP3932931C0 (en) 2024-11-20
JP2019069986A (ja) 2019-05-09
EP2834258A1 (en) 2015-02-11
EA201791916A1 (ru) 2018-07-31
EP3351552A1 (en) 2018-07-25
PT2834258T (pt) 2017-04-07
US10941177B2 (en) 2021-03-09
EA028928B1 (ru) 2018-01-31
JP2017206528A (ja) 2017-11-24
AU2017279590A1 (en) 2018-01-18
US20210253622A1 (en) 2021-08-19
US9481704B2 (en) 2016-11-01
ES2709071T3 (es) 2019-04-15
EP3210993B1 (en) 2018-12-12
JP6525441B2 (ja) 2019-06-05
CA2866381C (en) 2020-03-24
US20190016749A1 (en) 2019-01-17
MD4496C1 (ro) 2018-02-28
ES3005115T3 (en) 2025-03-13
KR20140135820A (ko) 2014-11-26
MD4496B1 (ro) 2017-07-31
IL256397A (en) 2018-02-28
JP2015509983A (ja) 2015-04-02
NZ629996A (en) 2016-10-28
SI2834258T1 (sl) 2017-04-26
IN2014DN08505A (show.php) 2015-05-15
EP2834258B1 (en) 2017-01-04
JP6242378B2 (ja) 2017-12-06
MD20140112A2 (ro) 2015-02-28
EP3351552B1 (en) 2021-05-19
EA201491548A1 (ru) 2015-02-27
HK1207083A1 (en) 2016-01-22
CA2866381A1 (en) 2013-09-19
MX2014011009A (es) 2014-10-13
US20170114086A1 (en) 2017-04-27
PL2834258T3 (pl) 2017-07-31
US11787832B2 (en) 2023-10-17
ES2621217T3 (es) 2017-07-03
CN106749272B (zh) 2019-08-30
ES2878087T3 (es) 2021-11-18
WO2013138236A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
IL256397A (en) Carba-nucleoside '2-converted analogs for antiviral therapy
IL228680A0 (en) Analogues of n nucleoside pyrimidine 1' - converted to antiviral therapy
AP3699A (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
IL252345A0 (en) Antiviral compounds
IL238578A0 (en) Spliceostatin analogs
IL239496A0 (en) Antiviral compounds
IL235062A0 (en) Compounds and methods for antiviral therapy
IL238785A0 (en) Nucleosides containing antiviral azasaccharides
SG10201703451RA (en) Antiviral compounds
IL232206A0 (en) Respiratory feedback device
PL3333173T3 (pl) Sposoby wytwarzania przeciwwirusowych analogów nukleotydów
SI2576534T1 (sl) 1'-substituirana-karba-nukleozidna predzdravila za antivirusno zdravljenje
GB201500662D0 (en) Biofeedback system
EP2699241A4 (en) ANTIVIRAL COMPOUNDS
EP2782585A4 (en) ANTIVIRAL PREPARATIONS
ZA201402374B (en) Antiviral compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed